Amyotrophic lateral sclerosis

The Lancet

Volumn 377, Issue 9769, 2011, Pages 942-955

  Kiernan, Matthew C ^a   Vucic, Steve ^b   Cheah, Benjamin C ^a   Turner, Martin R ^c   Eisen, Andrew ^d   Hardiman, Orla ^e   Burrell, James R ^a   Zoing, Margaret C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; CARBON 11; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXTROMETHORPHAN; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; LITHIUM CARBONATE; MACROGOL 3350; MINOCYCLINE; MORPHINE; MUSCLE RELAXANT AGENT; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYGEN 15; RILUZOLE; SODIUM CHLORIDE; SOMATOMEDIN C; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONFERENCE PAPER; CONSTIPATION; DEMENTIA; DEPRESSION; DIET; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISABILITY; DYSARTHRIA; DYSPHAGIA; DYSPNEA; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; HYPERSALIVATION; MENTAL INSTABILITY; MOLECULAR IMAGING; MOTOR NEURON DISEASE; MOUSE; MOUTH HYGIENE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OFF LABEL DRUG USE; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT EDUCATION; PHENOTYPE; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; SLEEP DISORDER; SPEECH THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79952486262     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61156-7     Document Type: Conference Paper

References (146)

1. Fang F, Kamel F, Sandler DP, Sparen P, Ye W. Maternal age, exposure to siblings, and risk of amyotrophic lateral sclerosis. Am J Epidemiol 2008; 167: 1281-86. (Pubitemid 351770551)
2. Sutedja NA, Veldink JH, Fischer K, et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 2009; 10: 302-09.
3. Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2009; 81: 385-90.
4. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007; 68: 1002-07. (Pubitemid 46569133)
5. Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology 2009; 72: 1640-45.
6. Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010; 465: 223-26.
7. Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives. Amyotroph Lateral Scler 2009; 10: 1-14.
8. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319: 1668-72. (Pubitemid 351432505)
9. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205-08.
10. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-11.
11. Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 2006; 38: 411-13.
12. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62. (Pubitemid 23087289)
13. Fallis BA, Hardiman O. Aggregation of neurodegenerative disease in ALS kindreds. Amyotroph Lateral Scler 2009; 10: 95-98.
14. van Es MA, Veldink JH, Saris CG, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009; 41: 1083-87.
15. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60: 147-51. (Pubitemid 26044186)
16. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-22. (Pubitemid 23213802)
17. Kuwabara S, Sonoo M, Komori T, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity. Muscle Nerve 2008; 37: 426-30. (Pubitemid 351501967)
18. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2005; 2: 147-59. (Pubitemid 43827916)
19. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66: 647-53. (Pubitemid 43739816)
20. Vucic S, Burke D, Kiernan MC. Diagnosis of motor neuron disease. In: Kiernan MC, ed. The Motor Neuron Disease Handbook. Sydney: Australasian Medical Publishing Company Limited, 2007: 89-115.
21. Ferguson TA, Elman LB. Clinical presentation and diagnosis of amyotrophic lateral sclerosis. NeuroRehabilitation 2007; 22: 409-16.
22. Duff y JR, Peach RK, Strand EA. Progressive apraxia of speech as a sign of motor neuron disease. Am J Speech Lang Pathol 2007; 16: 198-208.
23. Talbot K. Motor neuron disease: the bare essentials. Pract Neurol 2009; 9: 303-09.
24. Vucic S, Kiernan MC. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 849-52. (Pubitemid 47204591)
25. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66: 647-53. (Pubitemid 43739816)
26. Stambler N, Charatan M, Cedarbaum JM, Group ACTS. Prognostic indicators of survival in ALS. Neurology 1998; 50: 66-72. (Pubitemid 28106021)
27. Ramirez C, Piemonte MEP, Callegaro D, Da Silva HCA. Fatigue in amyotrophic lateral sclerosis: frequency and associated factors. Amyotroph Lateral Scler 2008; 9: 75-80. (Pubitemid 351584032)
28. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003; 74: S32-47.
29. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-33. (Pubitemid 44547757)
30. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59: 1077-79.
31. Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006; 66: 839-44. (Pubitemid 43739757)
32. Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006; 129: 868-76.
33. Le Ber I, Camuzat A, Berger E, et al. Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 2009; 72: 1669-76.
34. Laaksovirta H, Peuralinna T, Schymick JC, et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 2010; 9: 978-85.
35. Shatunov A, Mok K, Newhouse S, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol 2010; 9: 986-94.
36. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65: 586-90. (Pubitemid 41170719)
37. Flaherty-Craig C, Eslinger P, Stephens B, Simmons Z. A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology 2006; 67: 2070-72. (Pubitemid 44967396)
38. Merrilees J, Klapper J, Murphy J, Lomen-Hoerth C, Miller BL. Cognitive and behavioral challenges in caring for patients with frontotemporal dementia and amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11: 298-302.
39. Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009; 117: 137-49.
40. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology 2005; 64: 1222-26.
41. Vucic S, Kiernan MC. Pathophysiology of degeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009; 9: 255-72.
42. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7: 710-23. (Pubitemid 44267495)
43. Neusch C, Bahr M, Schneider-Gold C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve 2007; 35: 712-24. (Pubitemid 46835112)
44. Harwood CA, McDermott CJ, Shaw PJ. Physical activity as an exogenous risk factor in motor neuron disease (MND): a review of the evidence. Amyotroph Lateral Scler 2009; 10: 191-204.
45. Kasarskis EJ, Lindquist JH, Coff man CJ, et al. Clinical aspects of ALS in Gulf War veterans. Amyotroph Lateral Scler 2009; 10: 35-41.
46. Chio A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005; 128: 472-76. (Pubitemid 40380183)
47. Wicks P, Ganesalingham J, Collin C, Prevett M, Leigh NP, Al-Chalabi A. Three soccer playing friends with simultaneous amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8: 177-79. (Pubitemid 46887916)
48. Gallo V, Bueno-De-Mesquita HB, Vermeulen R, et al. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009; 65: 378-85.
49. Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 2002; 58: 956-59. (Pubitemid 34242075)
50. Bruijn LI, Beal MF, Becher MW, et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1997; 94: 7606-11.
51. Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281: 1851-54. (Pubitemid 28450505)
52. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004; 27: 723-49. (Pubitemid 39050419)
53. Liu R, Althaus JS, Ellerbrock BR, Becker DA, Gurney ME. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 1998; 44: 763-70. (Pubitemid 28516047)
54. Zetterstrom P, Stewart HG, Bergemalm D, et al. Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models. Proc Natl Acad Sci USA 2007; 104: 14157-62. (Pubitemid 350003351)
55. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999; 2: 50-56. (Pubitemid 30488940)
56. Watkins JC, Evans RH. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981; 21: 165-204.
57. Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 438-58.
58. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379-87. (Pubitemid 20262465)
59. Regan RF, Panter SS, Witz A, Tilly JL, Giff ard RG. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res 1995; 705: 188-98. (Pubitemid 26037364)
60. Maher P, Davis JB. The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 1996; 16: 6394-401. (Pubitemid 26337363)
61. Hensley K, Mhatre M, Mou S, et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 2006; 8: 2075-87. (Pubitemid 46489632)
62. Eisen A, Kim S, Pant B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve 1992; 15: 219-24.
63. Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, Beal MF. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis 2006; 22: 599-610. (Pubitemid 43832131)
64. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-16.
65. Lederer CW, Torrisi A, Pantelidou M, Santama N, Cavallaro S. Pathways and genes diff erentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 2007; 8: 26.
66. Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002; 80: 616-25. (Pubitemid 34809970)
67. Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2007; 66: 10-16. (Pubitemid 46066784)
68. Ellis DZ, Rabe J, Sweadner KJ. Global loss of Na, K-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2003; 23: 43-51. (Pubitemid 36050403)
69. Sasaki S, Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996; 47: 535-40. (Pubitemid 26324056)
70. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008; 105: 2052-57. (Pubitemid 351439463)
71. Staats KA, Van Den Bosch L. Astrocytes in amyotrophic lateral sclerosis: direct eff ects on motor neuron survival. J Biol Phys 2009; 35: 337-46.
72. Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 2008; 7: 409-16.
73. Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 2008; 4: e1000193.
74. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994; 124: 96-107.
75. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci 1999; 169: 2-12. (Pubitemid 29502500)
76. Kiernan MC. Motor neuron disease: a Pandora's box. MJA 2003; 178: 311-12. (Pubitemid 36503088)
77. Traynor BJ, Codd MB, Corr B, Forde C, Frost E. Hardiman O. Clinical features of Amyotrophic Lateral Sclerosis according to the El Escorial and Airlie House Diagnostic Criteria. Arch Neurol 2000; 57: 1171-76. (Pubitemid 30644664)
78. Ross MA, Miller RG, Berchert L, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998; 50: 768-72.
79. Beghi E, Balzarini C, Bogliun G, et al. Reliability of the El Escorial diagnostic criteria for amyotrophic lateral sclerosis. Neuroepidemiology 2002; 21: 265-70. (Pubitemid 36151496)
80. Chio A. ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999; 246 (suppl 3): III1-5.
81. Andersen PM, Borasio GD, Dengler R, et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 2007; 8: 195-213. (Pubitemid 47190223)
82. Rocha JA, Reis C, Simoes F, Fonseca J, Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol 2005; 252: 1435-47. (Pubitemid 41803831)
83. Vucic S, Pamphlett R, Wills EJ, Yiannikas C. Polyglucosan body disease myopathy: an unusual presentation. Muscle Nerve 2007; 35: 536-39. (Pubitemid 46542977)
84. Baloh RH, Rakowicz W, Gardner R, Pestronk A. Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle Nerve 2007; 36: 107-10. (Pubitemid 47016169)
85. Winhammar JM, Rowe DB, Henderson RD, Kiernan MC. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005; 4: 229-38. (Pubitemid 40381110)
86. Eisen A, Swash M. Clinical neurophysiology of ALS. Clin Neurophysiol 2001; 112: 2190-201. (Pubitemid 33153141)
87. Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000; 23: 1488-502.
88. Eisen A. Clinical electrophysiology of the upper and lower motor neuron in amyotrophic lateral sclerosis. Sem Neurol 2001; 21: 141-54. (Pubitemid 32578726)
89. Olney RK, Lewis RA, Putnam TD, Campellone JV Jr. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003; 27: 117-21. (Pubitemid 36083455)
90. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119: 497-503.
91. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 1985; 232: 295-300. (Pubitemid 15240721)
92. Li TM, Day SJ, Alberman E, Swash M. Diff erential diagnosis of motoneurone disease from other neurological conditions. Lancet 1986; 2: 731-33. (Pubitemid 16022221)
93. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125: 1887-95.
94. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 2000; 57: 109-13. (Pubitemid 30027638)
95. Belsh JM, Sciff man PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its reprecussions. J Neurol Sci 1996; 60: 110-16.
96. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009; 8: 94-109.
97. Goodin DS, Rowley HA, Olney RK. Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol 1988; 23: 418-20. (Pubitemid 18098258)
98. Ellis CM, Suckling J, Amaro E Jr, et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001; 57: 1571-78. (Pubitemid 33055472)
99. Chang JL, Lomen-Hoerth C, Murphy J, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 2005; 65: 75-80. (Pubitemid 40967780)
100. Turner MR, Hammers A, Allsop J, et al. Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8: 343-47. (Pubitemid 350176932)
101. Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44: 1933-38. (Pubitemid 24319224)
102. Gredal O, Rosenbaum S, Topp S, Karlsborg M, Strange P, Werdelin L. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997; 48: 878-81.
103. Beaulieu C. The basis of anisotropic water diff usion in the nervous system-a technical review. NMR Biomed 2002; 15: 435-55. (Pubitemid 36054508)
104. Ciccarelli O, Catani M, Johansen-Berg H, Clark C, Thompson A. Diff usion-based tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurol 2008; 7: 715-27.
105. Sage CA, Peeters RR, Gorner A, Robberecht W, Sunaert S. Quantitative diff usion tensor imaging in amyotrophic lateral sclerosis. Neuroimage 2007; 34: 486-99.
106. Kew JJ, Leigh PN, Playford ED, et al. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993; 116: 655-80. (Pubitemid 23203643)
107. Ludolph AC, Langen KJ, Regard M, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992; 85: 81-89.
108. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 994-1003. (Pubitemid 47562321)
109. Damoiseaux JS, Rombouts SA, Barkhof F, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA 2006; 103: 13848-53. (Pubitemid 44413996)
110. Mohammadi B, Kollewe K, Samii A, KrampflK, Dengler R, Munte TF. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol 2009; 217: 147-53.
111. Turner MR, Hammers A, Al Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C] flumazenil PET. Brain 2005; 128: 1323-29. (Pubitemid 40826186)
112. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008; 131: 1540-50. (Pubitemid 351806458)
113. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [(11)C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15: 601-09. (Pubitemid 38429975)
114. Mitchell RM, Freeman WM, Randazzo WT, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009; 72: 14-19.
115. Turner MR, Hammers A, Al Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C] flumazenil PET. Brain 2005; 128: 1323-29. (Pubitemid 40826186)
116. Bowen DM, Procter AW, Mann DM, et al. Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology 2008; 196: 603-10.
117. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. Proc Natl Acad Sci USA 2004; 101: 10901-06. (Pubitemid 38989558)
118. Jander S, Schroeter M, Saleh A. Imaging inflammation in acute brain ischemia. Stroke 2007; 38: 642-45. (Pubitemid 46184233)
119. Sykova E, Jendelova P. In vivo tracking of stem cells in brain and spinal cord injury. Prog Brain Res 2007; 161: 367-83. (Pubitemid 47023095)
120. Ng MC, Ho JT, Ho SL, et al. Abnormal diff usion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging 2008; 27: 8-13.
121. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-75. (Pubitemid 24227760)
122. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009; 106; 18809-14.
123. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007; 26: 1-13. (Pubitemid 46437445)
124. Leigh PN, Meininger V, Bensimon G, Cudkowicz M, Robberecht W. Minocycline for patients with ALS. Lancet Neurol 2008; 7: 119-20.
125. Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler 2008; 9: 16-23. (Pubitemid 351260368)
126. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007; 1: CD001447.
127. Bensimon GL, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994 330: 585-91. (Pubitemid 24065791)
128. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group II. Lancet 1996; 347: 1425-31. (Pubitemid 26161204)
129. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996-2000. J Neurol 2003; 250: 473-79.
130. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609-15. (Pubitemid 34516368)
131. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1227-33.
132. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005; 65: 1264-67.
133. Sathasivam S. Managing patients with amyotrophic lateral sclerosis. Eur J Intern Med 2009; 20: 355-58.
134. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Eff ects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5: 140-47. (Pubitemid 43109171)
135. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 67-71. (Pubitemid 39545334)
136. Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005; 12: 921-38. (Pubitemid 41823891)
137. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005; 2: 202-07. (Pubitemid 43827922)
138. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10: 113-17.
139. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005; 2: 202-07. (Pubitemid 43827922)
140. Bouteloup C, Desport JC, Clavelou P, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 2009; 256: 1236-42.
141. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, et al. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One 2009; 4: e5390.
142. Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler 2006; 7: 16-21.
143. Brownlee A, Palovcak M. The role of augmentative communication devices in the medical management of ALS. NeuroRehabilitation 2007; 22: 445-50.
144. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53. (Pubitemid 350116691)
145. The ALSUntangled Group. ALSUntangled update 1: investigating a bug (Lyme disease) and a drug (Iplex) on behalf of people with ALS. Amyotroph Lateral Scler 2009; 10: 248-50.
146. Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 151-54. (Pubitemid 33035909)